Apixaban
- Generic Name
- Apixaban
- Brand Names
- Eliquis, Apixaban Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N5O4
- CAS Number
- 503612-47-3
- Unique Ingredient Identifier
- 3Z9Y7UWC1J
- Background
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.
- Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism
- Associated Therapies
- -
Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 193565
- Registration Number
- NCT05321810
- Locations
- 🇯🇵
Pfizer, Tokyo, Japan
Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data
- Conditions
- Interventions
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 41875
- Registration Number
- NCT05264168
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company
- Target Recruit Count
- 234
- Registration Number
- NCT05262322
- Locations
- 🇬🇧
Royal Victoria Infirmary - Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom
🇬🇧Queen Elizabeth University Hospital - NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
🇬🇧Gloucestershire Royal Hospital - Gloucestershire Hospitals NHS Foundation Trust, Gloucester, United Kingdom
Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 529536
- Registration Number
- NCT05256797
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Apixaban in Patients With Left Ventricular Thrombus
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Saud Al Babtain Cardiac Center
- Target Recruit Count
- 50
- Registration Number
- NCT05208398
- Locations
- 🇸🇦
Saud AlBabtain Cardiac Center, Dammam, Saudi Arabia
Expanded Access for Apixaban
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT05187286
- Locations
- 🇺🇸
Childrens Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
- Conditions
- Interventions
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Anthos Therapeutics, Inc.
- Target Recruit Count
- 1655
- Registration Number
- NCT05171049
- Locations
- 🇮🇪
Bon Secour Hospital, Cork, Ireland
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸VA Connecticut Healthcare System, West Haven, Connecticut, United States
Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
- Conditions
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- VarmX B.V.
- Target Recruit Count
- 105
- Registration Number
- NCT05152420
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Scotmann Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT05088928
- Locations
- 🇵🇰
Rawalpindi Medical University, Rawalpindi, Punjab, Pakistan
High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
- Conditions
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05038228
- Locations
- 🇬🇧
Pfizer Investigator, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.